Skip to main content

Table 2 Absolute levels of host response markers at baseline by cytomegalovirus reactivation status

From: Effect of cytomegalovirus reactivation on the time course of systemic host response biomarkers in previously immunocompetent critically ill patients with sepsis: a matched cohort study

Marker Primary comparisona Secondary comparisonb
CMVs + (n = 37) CMV+ (n = 37)c P value CMVs− (n = 36) CMV+ (n = 36)c P value
Two days before CMV reactivation onset (t = −2)
 IL-6 4.4 (3.9–5.4) 4.3 (3.3–4.9) 0.08 4.3 (3.7–5.2) 4.3 (3.0–4.7) 0.22
 IL-8 3.6 (2.9–4.1) 3.3 (2.7–3.9) 0.35 3.5 (2.9–4.7) 3.4 (2.8–4.1) 0.23
 IL-18 6.5 (5.9–6.9) 6.4 (5.9–6.6) 0.46 6.3 (5.9–6.7) 6.4 (5.9–6.7) 0.77
 IP-10 6.5 (6.0–7.0) 6.3 (5.9–6.8) 0.13 6.3 (5.8–7.0) 6.3 (5.9–6.8) 0.68
 N-elastase 10.6 (10.3–11.1) 10.8 (10.2–11.0) 0.96 10.7 (10.5–11.1) 10.7 (10.2–11.0) 0.42
 IL-10 2.1 (1.4–3.3) 2.4 (2.0–3.1) 0.60 2.3 (1.6–3.2) 2.5 (1.9–3.1) 0.36
 IL-1RA 6.4 (5.8–7.3) 6.2 (5.7–7.0) 0.55 6.4 (5.7–6.9) 6.5 (5.7–7.1) 0.63
Day of CMV reactivation onset (t = 0)
 IL-6 4.2 (3.1–5.0) 3.9 (3.1–4.4) 0.25 4.1 (3.6–4.9) 3.8 (3.3–4.3) 0.16
 IL-8 3.5 (2.7–4.3) 3.1 (2.5–4.0) 0.36 3.6 (2.5–4.5) 3.2 (2.5–3.8) 0.16
 IL-18 6.4 (5.8–6.8) 6.2 (5.8–6.8) 0.67 6.3 (5.8–6.7) 6.2 (5.8–6.8) 0.89
 IP-10 6.3 (5.9–6.8) 6.4 (5.9–6.7) 0.75 6.2 (5.8–6.8) 6.5 (5.9–7.0) 0.46
 N-elastase 10.3 (10.1–10.8) 10.7 (10.2–11.0) 0.11 10.7 (10.3–10.9) 10.7 (10.2–11.0) 0.85
 IL-10 2.0 (1.6–3.0) 2.5 (1.9–2.9) 0.35 2.0 (1.6–2.7) 2.6 (1.9–3.0) 0.08
 IL-1RA 6.4 (5.4–7.1) 6.4 (5.5–7.0) 0.81 6.3 (5.5–7.2) 6.4 (5.4–6.9) 0.54
  1. Abbreviations: CMVs+ cytomegalovirus (CMV) seropositive without reactivation, CMV+ CMV reactivation, CMVs− CMV seronegative, IL interleukin, IP-10 interferon-gamma induced protein-10, N neutrophilic, RA receptor antagonist. Biomarker levels (in picograms per milliliter) were natural log-transformed and presented as median (Q1–Q3). Measurements were performed 2 days before CMV viremia onset and at the day of onset (defines t = 0 in viremia patient and corresponding ICU length of stay until that day determines t = 0 in matched patient without reactivation)
  2. aIn the primary comparison, patients with CMV reactivation were compared with matched CMV seropositive patients without reactivation
  3. bIn the secondary comparison, patients with CMV reactivation were compared with matched CMV seronegative patients
  4. cTwenty-eight patients with CMV reactivation are included in both matched comparisons